Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes.
Type 2 diabetes is a progressive disorder characterized by continuous deterioration in β-cell function requiring an escalation of therapeutic efforts in order to maintain glycemic control. Recent studies have demonstrated that the current antidiabetic treatments, including metformin, sulfonylureas and thiazolidinediones, are not durable, resulting in an increase of hemoglobin A1c over time with all three therapies. Many current antidiabetic treatments (sulfonylureas, thiazolidinediones and insulin) are associated with the undesirable feature of weight gain. In addition, sulfonylureas and insulin are associated with an increased risk for hypoglycemia. The unsatisfactory results with the current pharmacological therapies for Type 2 diabetes have encouraged the development of a number of novel treatments. Among these are the incretin-based therapies, which include glucagon-like peptide (GLP)-1 receptor agonists; this article focuses on one of these agonists, the human GLP-1 analog liraglutide. Liraglutide has been approved for use in Type 2 diabetic individuals in several countries, including Europe, the USA and Japan.